You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFesoterodine
Accession NumberDB06702
TypeSmall Molecule
GroupsApproved
Description

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Structure
Thumb
Synonyms
SynonymLanguageCode
FESONot AvailableNot Available
FesoterodineNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Toviaztablet, film coated, extended release4 mgoralPfizer Laboratories Div Pfizer Inc2008-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet, film coated, extended release8 mgoralPfizer Laboratories Div Pfizer Inc2008-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet, film coated, extended release4 mgoralPhysicians Total Care, Inc.2010-08-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet, film coated, extended release8 mgoralPhysicians Total Care, Inc.2010-09-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet, film coated, extended release8 mgoralU.S. Pharmaceuticals2008-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet, film coated, extended release4 mgoralU.S. Pharmaceuticals2008-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Toviaztablet (extended-release)4 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Toviaztablet (extended-release)8 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fesoterodine Fumarate
Thumb
  • InChI Key: MWHXMIASLKXGBU-RNCYCKTQSA-N
  • Monoisotopic Mass: 527.288302671
  • Average Mass: 527.649
DBSALT000085
Categories
CAS number286930-03-8
WeightAverage: 411.5769
Monoisotopic: 411.277344055
Chemical FormulaC26H37NO3
InChI KeyDCCSDBARQIPTGU-HSZRJFAPSA-N
InChI
InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1
IUPAC Name
2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate
SMILES
CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Phenol ester
  • Benzyl alcohol
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
PharmacodynamicsFesoterodine is a prodrug. In-vivo it is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate.
Mechanism of actionFesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
AbsorptionTmax (5-HMT): 5 hours post-adminitration of fesoterodine. AUC (0,∞)= 49.5 ng·h/ ml Bioavailability, 5-HMT = 52%
Volume of distribution

IV, 5-HMT: 169 L

Protein binding5-HMT: 50% to albumin and alpha1-acid glycoprotein
Metabolism

Metabolized by ubiquitous, nonspecific esterases to transform fesoterodine into 5-HMT Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites

Route of eliminationRenal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite Fecal: 7% Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4
Half life7-8 hours for the active metabolite 5-hydroxymethyl tolterodine
Clearance

5-HMT, healthy subjects: 14.4 L/h
5-HMT is also secreted into the nephron.

ToxicityRat, Oral, LD50: ~ 681 mg/kg Mouse, Oral, LD50: ~ 316 mg/kg Rat, Intravenous, NOAEL: 10 mg/kg Mouse, Intravenous, NOAEL: 10 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier+0.5648
Caco-2 permeable+0.7699
P-glycoprotein substrateSubstrate0.5268
P-glycoprotein inhibitor INon-inhibitor0.5556
P-glycoprotein inhibitor IINon-inhibitor0.625
Renal organic cation transporterInhibitor0.6025
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.5151
CYP450 3A4 substrateSubstrate0.5939
CYP450 1A2 substrateInhibitor0.6306
CYP450 2C9 substrateNon-inhibitor0.7227
CYP450 2D6 substrateInhibitor0.6255
CYP450 2C19 substrateNon-inhibitor0.7334
CYP450 3A4 substrateNon-inhibitor0.5718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6144
Ames testNon AMES toxic0.646
CarcinogenicityNon-carcinogens0.7213
BiodegradationNot ready biodegradable0.9385
Rat acute toxicity2.4003 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9196
hERG inhibition (predictor II)Inhibitor0.5602
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet (extended-release)oral4 mg
Tablet (extended-release)oral8 mg
Tablet, film coated, extended releaseoral4 mg
Tablet, film coated, extended releaseoral8 mg
PricesNot Available
Patents
CountryPatent NumberApprovedExpires (estimated)
United States68586501999-05-112019-05-11
United States73849801999-10-142019-10-14
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityHighly soluble MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00205 mg/mLALOGPS
logP5.45ALOGPS
logP5.7ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)10.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.08 m3·mol-1ChemAxon
Polarizability48.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Claus Meese, “CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF.” U.S. Patent US20090192224, issued July 30, 2009.

US20090192224
General Reference
  1. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.×. Pubmed
  2. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Pubmed
External Links
ATC CodesG04BD11
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (430 KB)
MSDSDownload (102 KB)
Interactions
Drug Interactions
Drug
AbirateroneCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
AclidiniumMay enhance the anticholinergic effect of Anticholinergic Agents.
AmiodaroneCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
AprepitantMay increase the serum concentration of CYP3A4 Substrates.
ArtemetherCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
AtazanavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
BoceprevirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BupropionCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
CelecoxibCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ChloroquineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ChlorpromazineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
CimetidineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
CinacalcetCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ClarithromycinCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ClobazamCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ClomipramineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ClozapineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
CocaineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DarifenacinCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
DarunavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DelavirdineCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
DesipramineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
DronedaroneCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
DuloxetineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
EliglustatCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
EthanolAlcohol (Ethyl) may enhance the CNS depressant effect of Fesoterodine.
FluoxetineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
HaloperidolCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ImipramineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
IndinavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
IsoniazidCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ItoprideAnticholinergic Agents may diminish the therapeutic effect of Itopride.
ItraconazoleCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
LopinavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
LorcaserinCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
LumefantrineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
MethadoneCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
MethotrimeprazineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
MetoclopramideAnticholinergic Agents may diminish the therapeutic effect of Metoclopramide.
MianserinMay enhance the anticholinergic effect of Anticholinergic Agents.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MirabegronAnticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
NefazodoneCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
NelfinavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
NilotinibCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
PanobinostatCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ParoxetineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
Potassium ChlorideAnticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.
PramlintideMay enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.
PromazineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
QuinidineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
QuinineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
RitonavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
SaquinavirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
SecretinAnticholinergic Agents may diminish the therapeutic effect of Secretin.
SertralineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
TelaprevirCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
TelithromycinCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
ThioridazineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
TiclopidineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
TiotropiumAnticholinergic Agents may enhance the anticholinergic effect of Tiotropium.
TipranavirCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TopiramateAnticholinergic Agents may enhance the adverse/toxic effect of Topiramate.
TranylcypromineCYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.
VoriconazoleCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
Food Interactions
  • Take with or without food.

Targets

1. Muscarinic acetylcholine receptor M3

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M3 P20309 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. Pubmed

2. Muscarinic acetylcholine receptor M4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M4 P08173 Details

References:

  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. Epub 2008 Nov 24. Pubmed

3. Muscarinic acetylcholine receptor M1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M1 P11229 Details

References:

  1. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. Pubmed

4. Muscarinic acetylcholine receptor M2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M2 P08172 Details

References:

  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. Epub 2008 Nov 24. Pubmed

5. Muscarinic acetylcholine receptor M5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M5 P08912 Details

References:

  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. Epub 2008 Nov 24. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. Pubmed
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the Moderate CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fesoterodine in Healthy Subjects. Br J Clin Pharmacol. 2011 May 5. doi: 10.1111/j.1365-2125.2011.04007.×. Pubmed
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. Epub 2009 Apr 4. Pubmed
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. Pubmed

2. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. Pubmed
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the Moderate CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fesoterodine in Healthy Subjects. Br J Clin Pharmacol. 2011 May 5. doi: 10.1111/j.1365-2125.2011.04007.×. Pubmed
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. Epub 2009 Apr 4. Pubmed
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW: Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. Pubmed

Comments
comments powered by Disqus
Drug created on May 06, 2010 10:47 / Updated on September 16, 2013 18:04